F. Adam Abulawi

New York
  • 1271 Avenue of the Americas
  • New York, NY 10020
  • USA
 
 

F. Adam Abulawi is an associate in the New York office of Latham & Watkins and a member of the Mergers & Acquisitions and Private Equity Practices.

Mr. Abulawi represents public and private companies, including strategic and financial investors, in connection with domestic and cross-border mergers, acquisitions, divestitures, joint ventures, carve-outs, reorganizations, and general corporate matters.

Mr. Abulawi regularly advises clients across a broad array of industries, including media, entertainment, technology, retail, consumer products, and real estate. In addition, he actively provides pro bono counsel to artists and non-profit organizations through Volunteer Lawyers for the Arts, and previously served on the board of Brooklyn Ballet.

Prior to joining Latham, Mr. Abulawi served as in-house counsel to an American telecommunications and mass media company, and was a corporate associate in the New York office of another leading international law firm.

Mr. Abulawi’s representative matters include advising:

  • ArcLight Capital Partners in its acquisition of a solar power platform in Puerto Rico from Sonnedix, the global solar independent power producer
  • Syneos Health (NASDAQ), a fully integrated biopharmaceutical solutions organization, in its acquisition of RxDataScience, a leading healthcare-focused data analytics, data management, and artificial intelligence company
  • The New Home Company (NYSE), a new generation homebuilder, in its US$173 million sale to funds managed by Apollo Global Management
  • The Board Committee of Viacom (NASDAQ) in its US$30 billion merger with CBS*
  • Hasbro (NASDAQ), a global play and entertainment company, in its US$3.8 billion acquisition of Entertainment One*
  • J.D. Power, a provider of analytics and market research, in its US$1.8 billion sale to Thoma Bravo*
  • Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson (NYSE), in its US$750 million acquisition of all rights to the investigational compound bermekimab from XBiotech*

*Matter handled prior to joining Latham

 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.